- ￥6768
- AntibodySystem
- 0.31-5 μg/mL
- 0.156 μg/ml
- KDD17401
- France
- 2025年07月09日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
999
- 供应商：
AntibodySystem
- 检测范围：
0.31-5 μg/mL
- 检测方法：
Colorimetric
- 应用：
ELISA
- 标记物：
HRP
- 样本：
Plasma, Serum
- 灵敏度：
0.156 μg/ml
- 规格：
96T
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 检测方法 | Colorimetric |
| 精准度 |
CV<20% |
| 样本类型 | Plasma, Serum |
| 实验类型 | Quantitative |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 背景 | Edrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM. |
| 别名 | 17-1A, CAS: 156586-89-9 |
| 运输 | 2-8 ℃ |
| 备注 | For Research Use Only. |
Established in 2019 in France, AntibodySystem Laboratories SAS is a standalone brand dedicated to the production of protein and antibody reagents for life science research. We aim to empower researchers globally with high-quality products for fundamental scientific research. AntibodySystem offers a broad selection, including traditional polyclonal antibodies, essential housekeeping antibodies, tag antibodies, high-potency proteins, functional antibodies for in vivo use, low-background flow antibodies, highly specific nanobodies, unique small molecule antibodies, high-quality phospho-specific antibodies, DNA/RNA antibodies, and PEG antibodies, among others.
AntibodySystem's product range supports research in multiple fields, encompassing 48 types of viruses, superbugs, parasites, oncology, Alzheimer's, Parkinson's, hypersensitivity, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
